CX516, a positive modulator of the glutamatergic alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor, improves performance in tasks requiring learning and memory in animals. CX516 was added to clozapine in 4-week, placebo-controlled, dose-finding (N = 6) and fixed-dose (N = 13) trials. CX516 was tolerated well and was associated with moderate to large, between-group effect sizes compared with placebo, representing improvement in measures of attention and memory. These preliminary results suggest that CX516 and other "ampakines" hold promise for the treatment of schizophrenia.

Polytherapy was used by one-third of patients initially and at one year, antidepressant use was highly prevalent initially and later, but lack of treatment was prevalent at one year. Plausible clinical and treatment factors were associated with sustained mood stabilizer adherence.

Antidepressants were the first-choice agent twice as often as mood stabilizers. Lithium was sustained longer than monotherapy with other mood stabilizers. Time to augmentation was much shorter than time to change or discontinuation.

A dherence to multiple sclerosis (MS) diseasemodifying therapies, such as interferons, has been linked to improved treatment outcomes and reduced health-care costs. 1,2 Reasons for poor patient adherence to prescribed MS therapies include frequency of administration and adverse events, such as flu-like symptoms (FLSs) and injection-site reactions (ISRs), associated with interferon beta treatments. [3][4][5][6][7][8] Peginterferon beta-1a is a pegylated form of interferon beta-1a approved for the treatment of relapsing forms of MS. The safety and efficacy of peginterferon beta-1a 125 μg administered subcutaneously every 2 or 4 weeks

No abstract